J. Mölgaard

发表

The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.

S. Nilsson, I. Holme, G. Walldius, 1996, Atherosclerosis.

Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.

S. Nilsson, G. Walldius, L. Kaijser, 1988, The American journal of cardiology.

Decreased mitogenic activity in hypercholesterolaemic plasma

A. Olsson, J. Mölgaard, J. Nilsson, 1990, Journal of internal medicine.

Alfalfa seeds lower low density lipoprotein cholesterol and apolipoprotein B concentrations in patients with type II hyperlipoproteinemia.

H. von Schenck, A. Olsson, J. Mölgaard, 1987, Atherosclerosis.

Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia.

H. von Schenck, A. Olsson, J. Mölgaard, 1991, Atherosclerosis.

Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.

S. Nilsson, I. Holme, G. Walldius, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Apolipoprotein profiles in randomly selected smokers and matched controls.

A. Olsson, J. Mölgaard, 1990, Advances in experimental medicine and biology.

Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication.

O. Faergeman, A. Olsson, L. U. Gerdes, 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication

A. Olsson, J. Mölgaard, A. Holm, 1992, Journal of internal medicine.

The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).

S. Nilsson, I. Holme, G. Walldius, 1994, The American journal of cardiology.

Relations between smoking, food intake and plasma lipoproteins.

A. Olsson, J. Mölgaard, 1990, Advances in experimental medicine and biology.

Efficacy and safety of simvastatin for high-risk hypercholesterolemia.

A. Olsson, J. Mölgaard, S. Wärjerstam-Elf, 1999, The American journal of cardiology.

The Future of Pharmacological Therapy for Risk Factor Reduction

A. Olsson, J. Mölgaard, 2012, Drugs.

Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolaemia.

A. Olsson, J. Mölgaard, J. Johansson, 1991, Atherosclerosis.

SYNVINOLIN IN HYPERCHOLESTEROLAEMIA

J. Mölgaard, A. Olsson, H. Schenk, 1986, The Lancet.

Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia

A. Olsson, J. Mölgaard, H. Schenck, 2004, European Journal of Clinical Pharmacology.

Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia.

H. von Schenck, A. Olsson, J. Mölgaard, 1988, European heart journal.

The relation of coronary and peripheral arterial disease to the severity of femoral atherosclerosis in hypercholesterolaemia

S. Nilsson, I. Holme, G. Walldius, 1994, Journal of internal medicine.

Predilection of atherosclerosis for the inner curvature in the femoral artery. A digitized angiography study.

O Smedby, O. Smedby, G. Walldius, 1995, Arteriosclerosis, thrombosis, and vascular biology.

The ability of non-invasive physiological tests to detect arterial occlusions in the lower extremity. An ROC study with particular regard to recruitment of patients for clinical trials.

S. Nilsson, G. Walldius, L. Kaijser, 1998, Upsala journal of medical sciences.

Probucol treatment decreases serum concentrations of diet-derived antioxidants.

I. Holme, G. Walldius, L. Elinder, 1995, Arteriosclerosis, thrombosis, and vascular biology.